{"id":18,"date":"2022-12-05T17:00:40","date_gmt":"2022-12-05T17:00:40","guid":{"rendered":"http:\/\/192.168.10.30\/?page_id=18"},"modified":"2023-02-14T09:57:01","modified_gmt":"2023-02-14T09:57:01","slug":"trial-complexity","status":"publish","type":"page","link":"https:\/\/rttrialsqa.org.uk\/?page_id=18","title":{"rendered":"Trial Complexity"},"content":{"rendered":"\n

RTTQA Trial Complexity<\/h1>\n\n\n\n

The RTTQA Group have categorised the QA component of radiotherapy trials as Minimal, Basic, Moderate, and Complex.<\/p>\n\n\n\n

Please see the table below for QA complexity rating and contact details for trials in the current RTTQA Group portfolio.<\/p>\n\n\n\n\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Trial<\/th>QA category<\/th>QA email<\/th>\n<\/tr>\n<\/thead>\n
ABC-07<\/td>Complex<\/td>davideaton@nhs.net<\/td>\n<\/tr>\n
ADePT-DDR<\/td>Moderate<\/td>adeptqa.enh-tr@nhs.net<\/td>\n<\/tr>\n
ALL-RIC<\/td>Basic<\/td>patricia.diez@nhs.net<\/td>\n<\/tr>\n
APHRODITE<\/td>Complex<\/td>aphroditeqa.enh-tr@nhs.net<\/td>\n<\/tr>\n
ARCADIAN<\/td>Basic<\/td>arcadianqa.enh-tr@nhs.net<\/td>\n<\/tr>\n
ARTEMIS<\/td>Moderate<\/td>artemisqa.enh-tr@nhs.net<\/td>\n<\/tr>\n
ATLANTA<\/td>Moderate<\/td>ATLANTA.qa@nhs.net<\/td>\n<\/tr>\n
ATNEC<\/td>Complex<\/td>atnecqa.enh-tr@nhs.net<\/td>\n<\/tr>\n
BRIOChe<\/td>Moderate<\/td>briocheqa.enh-tr@nhs.net<\/td>\n<\/tr>\n
CEDAR<\/td>Moderate<\/td>CEDAR.RTTQA@wales.nhs.net<\/td>\n<\/tr>\n
CHARIOT<\/td>Moderate<\/td>CHARIOT.RTTQA@wales.nhs.uk<\/td>\n<\/tr>\n
CHRONOS<\/td>Moderate<\/td>chronos.qa@nhs.net<\/td>\n<\/tr>\n
CompARE<\/td>Moderate<\/td>COMPAREqa.enh-tr@nhs.net<\/td>\n<\/tr>\n
CONCORDE<\/td>Basic<\/td>concordeqa.enh-tr@nhs.net<\/td>\n<\/tr>\n
CORINTH<\/td>Complex<\/td>CORINTH.RTTQA@wales.nhs.uk<\/td>\n<\/tr>\n
CRAIN<\/td>Basic<\/td>TBC<\/td>\n<\/tr>\n
HALT<\/td>Complex<\/td>haltqa.enh-tr@nhs.net<\/td>\n<\/tr>\n
HIT-MESO<\/td>Complex<\/td><\/td>\n<\/tr>\n
INPACT<\/td>Complex<\/td>InPact.RTTQA@wales.nhs.uk<\/td>\n<\/tr>\n
INSPIRE<\/td>Basic<\/td>jan.taprogge@nhs.net<\/td>\n<\/tr>\n
INTERLACE<\/td>Complex<\/td>patricia.diez@nhs.net<\/td>\n<\/tr>\n
NeoRT<\/td>Basic<\/td>neortqa.enh-tr@nhs.net<\/td>\n<\/tr>\n
PACE-NODES<\/td>Complex<\/td>pace-nodes.rtqa@nhs.net<\/td>\n<\/tr>\n
PARABLE<\/td>Complex<\/td>enh-tr.parableqa@nhs.net<\/td>\n<\/tr>\n
PARADIGM<\/td>Basic<\/td>PARADIGM.enh-tr@nhs.net<\/td>\n<\/tr>\n
PARADIGM 2<\/td>Basic<\/td>PARADIGMqa.enh-tr@nhs.net<\/td>\n<\/tr>\n
PART
\n<\/td>		Basic<\/td><\/td>\n<\/tr>\n
PATHOS<\/td>Moderate<\/td>PATHOSqa.enh-tr@nhs.net<\/td>\n<\/tr>\n
PEARL<\/td>Complex<\/td>PEARL.RTTQA@wales.nhs.uk<\/td>\n<\/tr>\n
PEARLS<\/td>Complex<\/td>pearls.rtqa@nhs.net<\/td>\n<\/tr>\n
PIVOTALboost<\/td>Complex<\/td>pivotalboost.trial@nhs.net<\/td>\n<\/tr>\n
PLATO<\/td>Complex<\/td>PLATO.RTTQA@wales.nhs.uk<\/td>\n<\/tr>\n
PNET5<\/td>Complex<\/td>james.talbot@nhs.net,\u00a0ruth.colgan1@nhs.net<\/td>\n<\/tr>\n
POPS<\/td>Moderate<\/td>pops.trial@nhs.net<\/td>\n<\/tr>\n
POSNOC<\/td>Basic<\/td>POSNOCqa.enh-tr@nhs.net<\/td>\n<\/tr>\n
PRIME-RT<\/td>Basic<\/td>PrimeRT.RTTQA@wales.nhs.uk<\/td>\n<\/tr>\n
PROTIEUS<\/td>Complex<\/td>TBC<\/td>\n<\/tr>\n
PROTIS<\/td>Complex<\/td>TBC<\/td>\n<\/tr>\n
RAD-IO<\/td>Basic<\/td>radIOqa.enh-tr@nhs.net<\/td>\n<\/tr>\n
RATIO<\/td>Basic<\/td>TBC<\/td>\n<\/tr>\n
SARON<\/td>Complex<\/td>SARONqa.enh-tr@nhs.net<\/td>\n<\/tr>\n
SCALOP2<\/td>Complex<\/td>scalop2.rttqa@wales.nhs.uk<\/td>\n<\/tr>\n
SCC-AFTER<\/td>Basic<\/td>smallqa.enh-tr@nhs.net<\/td>\n<\/tr>\n
SCOPE2<\/td>Complex<\/td>SCOPE2.RTTQA@wales.nhs.uk<\/td>\n<\/tr>\n
SIOP EPENDYMOMA II<\/td>Complex<\/td>ccf-tr.ependymoma2qa@nhs.net<\/td>\n<\/tr>\n
SMALL<\/td>Basic<\/td>smallqa.enh-tr@nhs.net<\/td>\n<\/tr>\n
SOPRANO<\/td>Moderate<\/td>TBC<\/td>\n<\/tr>\n
STAMPEDE<\/td>Basic<\/td>Olivia.Naismith@rmh.nhs.uk<\/td>\n<\/tr>\n
STAMPEDE-SABR<\/td>Moderate<\/td>TBC<\/td>\n<\/tr>\n
STAR-TREC<\/td>Moderate<\/td>STAR-TRec.RTTQA@wales.nhs.uk<\/td>\n<\/tr>\n
SYSTEMS2<\/td>Minimal<\/td>nicki.groom@nhs.net<\/td>\n<\/tr>\n
TORPEDO<\/td>Complex<\/td>torpedoqa.enh-tr@nhs.net<\/td>\n<\/tr>\n
TOURIST<\/td>Complex<\/td>torpedoqa.enh-tr@nhs.net<\/td>\n<\/tr>\n
TRAP<\/td>Minimal<\/td>trapqa.enh-tr@nhs.net<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

RTTQA Trial Complexity The RTTQA Group have categorised the QA component of radiotherapy trials as Minimal, Basic, Moderate, and Complex. Please see […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-18","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/18","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18"}],"version-history":[{"count":6,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/18\/revisions"}],"predecessor-version":[{"id":405,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/18\/revisions\/405"}],"wp:attachment":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}